歌礼制药-B的口服小分子Glp-1药物Asc30在参与肥胖或超重的患者中进行的美国13周二期研究中,展现出调整后7.7%的体重减轻,并且具备更好的胃肠耐受性。
歌礼制药-B的口服小分子Glp-1药物Asc30在参与肥胖或超重的患者中进行的美国13周二期研究中,展现出调整后7.7%的体重减轻,并且具备更好的胃肠耐受性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.